Published Paper Details:

Solid lipid nanoparticles (SLNs) have emerged as promising carriers for ocular drug delivery systems due to their unique characteristics. These nanoparticles are composed of biocompatible lipids, providing a stable matrix for drug encapsulation. The solid nature of SLNs offers improved physical stability, preventing drug leakage and degradation during storage. The small particle size of SLNs facilitates efficient penetration through ocular barriers, enhancing drug bioavailability within the eye. Moreover, SLNs can be surface-modified to control drug release rates and improve targeting specificity. In the context of ocular drug delivery, SLNs offer advantages such as reduced systemic side effects and prolonged drug retention in the eye, leading to enhanced therapeutic outcomes. The biodegradable nature of lipid-based carriers further contributes to their safety profile. Overall, solid lipid nanoparticles represent a promising platform for the development of effective and safe ocular drug delivery systems, addressing the challenges associated with conventional formulations and improving patient compliance